AI in pharmacy means using machine learning and language models to help pharmacists and staff with work that already runs through the pharmacy system. The projects that hold up are narrow ones: ranking interaction alerts, forecasting stock and drafting prior authorization requests for a person to check.
This guide looks at those three uses, the FDA, HIPAA and CMS rules that touch them, how to run a pilot, what pharmacist review should look like, how to govern the models and where these projects tend to fail.
What does AI in pharmacy mean in practice?
Adding AI to your pharmacy software?
Agnotic Technologies builds AI features into pharmacy systems for clients, with pharmacist approval and audit logging designed in from the start.
AI in pharmacy is software that uses statistical or language models to support pharmacy decisions and paperwork, such as prioritizing drug interaction alerts, forecasting inventory and drafting prior authorization requests. In each case a pharmacist or trained staff member reviews the output before it affects a patient, an order or a payer submission.
That review step is the main design constraint. A model that writes directly to a claim, an order or a patient message with nobody in between is a different product with different risks, and few pharmacies should start there.
AI also depends on the system beneath it. Models read dispensing history, profiles and claim responses from the pharmacy platform, so gaps in that data become gaps in every suggestion.
Which pharmacy tasks suit AI?
Three tasks suit AI because they are high in volume, rich in data and already checked by a person: interaction screening support, inventory forecasting and prior authorization drafting.
Interaction screening support
Rules-based interaction screening fires on every drug pair in its knowledge base, whatever the patient's context. A model can rank those alerts using labs, age, dose, renal function and history, so the pharmacist sees the ones most likely to matter first.
The model ranks; it never hides. Every alert from the screening database stays visible, and the pharmacist's decision on each one is recorded, which also builds the labeled data needed to evaluate the ranking.
Evaluation asks a simple question: were the alerts pharmacists acted on ranked near the top? Score that on held-out weeks of data, and report inpatient and outpatient results separately, since the alert mix differs between them.
Inventory forecasting
Forecasting models predict demand by NDC from dispensing history, refill due dates, seasonal patterns and local prescribing. The output is a suggested order quantity that the buyer accepts or changes, not an automatic purchase.
Forecasts earn their keep on expensive specialty drugs and short-dated items, where overstock and stockouts both cost money. Shortage notices and recalls must override the model, because history cannot predict a supply interruption.
Judge a forecast by the outcomes the buyer cares about, such as stockouts avoided and stock written off as expired, not only by forecast error. A model with a smaller error can still be the worse choice if it misses the drugs that matter most.
Prior authorization drafting
When a claim rejects for prior authorization, a language model can draft the request from the chart: diagnosis, therapies already tried, relevant labs and the prescriber's rationale. Staff check every field against the record before anything is sent.
Electronic prior authorization for pharmacy-benefit drugs runs on NCPDP SCRIPT prior authorization transactions. Drafts should fill those structured fields rather than produce a free-text letter that someone has to retype.
Ground the model in the chart and in the plan's published criteria. Retrieval that pulls the relevant notes and the payer policy, with each drafted field citing its source, gives the reviewer something to check instead of a fluent paragraph to trust.
Which rules apply to AI in pharmacy?
No single rule covers pharmacy AI. Three federal rules decide most of the design, depending on what the tool does and whose data it uses.
- FDA CDS guidance: FDA's final Clinical Decision Support Software guidance, issued 6 Jan 2026 and re-issued 29 Jan 2026, explains which software functions for health care professionals fall outside the device definition, including the criterion that the professional can independently review the basis for a recommendation.
- Business associates: Under 45 CFR 164.502(e), an AI vendor that receives or maintains PHI on behalf of a pharmacy that is a HIPAA covered entity is a business associate and needs a business associate agreement before it receives PHI.
- Prior authorization scope: CMS-0057-F sets prior authorization API and decision timeframe requirements for medical items and services, and its prior authorization policies exclude drugs.
Drug prior authorization rules are still moving, and CMS has proposed bringing drugs under similar requirements. Design the drafting tool so the output format and payer rules are configuration, not model behavior, and the tool can follow a rule change without retraining.
Fairness belongs in the same review. Check how a ranking or drafting tool performs for different patient groups, because a model that works well on average can still work worse for some patients, and decision support tools are not exempt from nondiscrimination duties.
Device status and device class are separate questions. A tool that falls outside the CDS carve-out is not automatically a device, but the analysis belongs in the project record before launch, not after.
How do you run an AI pilot in a pharmacy?
Run a pilot on one use at one site, with the review rule written before any model is built. The sequence below keeps the pharmacy workflow safe while the model proves itself.
- 1. Pick one use and one site: For example, alert ranking in one hospital pharmacy, or order suggestions for one category of specialty drugs.
- 2. Write the review rule: Name who reviews each output, what they may change and what happens when they reject it.
- 3. Assemble the data: Pull history from the pharmacy system, sign a business associate agreement with any vendor that touches PHI, and drop fields the model does not need.
- 4. Measure a baseline: Record the current process, such as time from rejection to prior authorization submission or how often alerts lead to action, before the model runs.
- 5. Run silently: Let the model score live cases without showing staff, and compare its output with what pharmacists actually did.
- 6. Show it to reviewers: Turn suggestions on for a small group, log every accept, edit and reject, and review the edits each week.
- 7. Decide: Expand, change or stop based on the baseline comparison and reviewer feedback, and record the decision for governance.
Choose reviewers who do the work today, not only champions of the project. Their edits are the most honest test of the tool, and their trust decides whether it is used after the pilot ends.
Silent mode is the cheapest safety check in the sequence. It shows how the model would have behaved on real work without any patient or payer seeing the output, and it tends to expose data gaps that a test set missed.
What pharmacist review should look like
A good review screen makes the model's reasoning checkable in seconds. If a pharmacist has to search the chart to confirm a draft, the tool has saved nothing.
- Source links: Each drafted field or ranked alert links to the record it came from, such as the lab value, the prior fill or the diagnosis code.
- Visible uncertainty: Low-confidence items are flagged, and empty fields stay empty rather than being filled with a guess.
- Edit capture: Changes the reviewer makes are stored beside the original draft, so the team can see where the model goes wrong.
- No auto-submit: Nothing goes to a payer, prescriber or patient until a named user approves it.
- Fallback path: If the model service is down, the workflow continues without it and the queue shows that suggestions are unavailable.
These controls also support the FDA criterion on independent review, because the professional sees the basis for each suggestion instead of trusting a score.
How should pharmacy AI be governed?
Governance means a named owner, a written intended use and a monitoring plan for every model. NIST AI 100-1, the AI Risk Management Framework, offers a voluntary structure through four functions: govern, map, measure and manage.
Monitoring in a pharmacy covers drift as formularies and prescribing patterns change, performance across patient groups, and a review of each case where a wrong suggestion reached a reviewer.
Keep a model inventory with version, training data dates, intended use and owner. When a payer, auditor or board member asks how a tool works, that inventory is the answer.
Vendors selling AI features should describe each model's training data, intended use, known limits and update schedule. Ask for that in writing during procurement, together with how the vendor will tell the pharmacy about a model change.
Where pharmacy AI projects go wrong
- Automating the decision: A tool built to clear alerts or submit requests on its own removes the review step the design depends on.
- Learning from overrides: Treating past override decisions as ground truth teaches the model the habits of a busy shift, including the bad ones.
- Ignoring supply events: Forecasts built only on dispensing history over-order during a shortage or recall and under-order after it ends.
- Letter-style drafts: Prior authorization drafts written as prose do not map to the structured fields payers expect, so staff retype them.
- Consumer chatbots: Staff paste patient details into a public AI tool that has no business associate agreement.
- No stop rule: The pilot has no exit criteria, so a tool that does not help stays in the workflow.
Most of these trace back to skipping steps 2 and 4 of the pilot: no written review rule and no baseline to compare against.
How Agnotic can help
Pharmacy AI is mostly integration and review design, with the model as one component. Agnotic builds these features for clients: alert ranking that sits beside the existing screening database, forecasting tied to purchasing, and prior authorization drafts mapped to NCPDP SCRIPT fields, each with logging and a pharmacist approval step.
When the underlying pharmacy platform needs work first, the guide to technology in pharmacy covers e-prescribing, claims, EPCS and product tracing.
Plan an AI pilot for your pharmacy
Talk to Agnotic about one well-scoped AI feature, built into your pharmacy software with review and audit controls.
Related reading on Agnotic
Continue with technology in pharmacy, HIPAA and AI apps, healthcare AI trends and clinical decision support.
